This comprehensive case study explores Kymanox’s approach to FDA regulatory approval and combination product development through cross-functional project management and technical documentation excellence. Our team of Subject Matter Experts (SMEs) collaborated closely with pharmaceutical stakeholders to implement measurable improvements across regulatory submission preparation, technical documentation, quality systems, and product format expansion from Prefilled Syringe (PFS) to Autoinjector (AI) platforms.
CHALLENGE
SOLUTION
RESULTS
- Pharmaceutical client required FDA regulatory support to obtain approval for PFS format of existing commercial therapy already available in vial/syringe presentation.
- Comprehensive combination product expertise needed across technical development and quality systems to navigate complex FDA regulatory requirements and approval pathways.
- Strategic regulatory submission content development essential ensuring comprehensive documentation support safety, efficacy, and quality of PFS format.
- Future product format expansion planning requiring scalable regulatory strategy support AI development in EU market under separate project initiative.
- Provided comprehensive project management and strategic regulatory consulting to client cross-functional project team ensuring alignment with FDA combination product requirements.
- Created detailed technical documentation and regulatory submission content for PFS product demonstrating compliance with FDA quality, safety, and efficacy standards.
- Coordinated cross-functional stakeholders including regulatory affairs, quality assurance, manufacturing, and technical teams ensuring cohesive submission strategy.
- Developed scalable regulatory framework supporting future product format expansion and international market access.
- Subsequently supported strategic bridging to AI format in EU market under separate project leveraging PFS development knowledge and regulatory expertise.
- Successfully achieved FDA approval for PFS format in 2022 expanding commercial therapy availability and improving patient convenience.
- Delivered comprehensive regulatory submission content meeting FDA combination product expectations without major deficiencies or delays.
- Established foundation for product format expansion with EU AI approval pending, demonstrating successful regulatory strategy scalability.
- Created reusable regulatory framework and technical documentation supporting ongoing product lifecycle management and future format development initiatives.